Overview

The safety and efficacy of the chimeric antigen receptor (CAR)-T, a CD19-targeting, TRAC and Power3 (SPPL3) double genes deleted allogeneic CAR-T cell product, are undergoing rigorous evaluation in non-Hodgkin's lymphoma (NHL) subjects from our ATHENA trial (NCT06014073). Unexpectedly, expansion of the initial residual CD3-positive CAR T from products were measured in patients' peripheral blood (PB) without exception. Accompanying with host immune reconstitution and appearance of the detectable B cells, the CD3-positive allogenic CAR T cells exhibited a compelling amplification advantage over CD3-negative CAR T cells. The amplification of CD3-positive CAR T cell population dynamically suppressed host B cell recovery, and presumably surveilled the recurrence or progression of tumors, but did not induce typical Graft-versus-host-disease (GvHD). Additionally, a series of in vitro experiments illustrated that the HLA-mismatched fratricide between host T cells and TCR-reserved Power3 (SPPL3)-deleted allogenic CAR T cells was markedly slashed, which in combination with our observed clinical safety date supported the notion that only genomic deletion of Power3 (SPPL3) gene in allo-CAR T cells is sufficient to overcome GvHD and host T cell-mediated rejection response.

In the ATHENA-2 study, our design is to preserve the expression of the TCR on T cells from healthy donors while selectively disabling the Power3 (SPPL3) gene to prepare ATHENA-2 CAR T cells. This approach harnesses the tonic signaling of CAR T cells, resulting in enhanced persistence and improved response to treatment. The purpose of this study is to evaluate the safety and efficacy of ATHENA-2 in B-cell NHL.

Eligibility

Inclusion Criteria:

1. Age 18-70 (inclusive).
2. Subjects who meet the following requirements:

   2.1 Histologically confirmed refractory/relapsed B cell NHL, including the following types defined by WHO 2016:

   • Diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS);
   • Primary mediastinal (thymic) large B-cell lymphoma (PMBCL);
   • Transformed follicular lymphoma (TFL);
   • High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBCL);
   • Follicular lymphoma (FL);
   • Mantle cell lymphoma (MCL) (pathologically confirmed, with documentation of monoclonal B cells that have a chromosome translocation t(11;14)(q13;q32) and/or overexpress cyclin D1);
   • Marginal zone lymphoma (MZL), including nodal or splenic marginal zone B-cell lymphoma and mucosa-associated lymphoid tissue (MALT) lymphoma.

     2.2 Relapsed disease is defined as disease progression (PD) after achieving disease
     remission (including CR and PR) with the latest standard regimen.
     2.3 Refractory disease is defined as no CR to first-line therapy:
       -  Evaluation of PD (never reached response or SD) after standard first-line
          treatment, or
       -  SD as best response after at least 4 cycles of first-line therapy (eg,4 cycles
          of R-CHOP), or
       -  PR as best response after at least 6 cycles and biopsy-proven residual disease
          or disease progression ≤ 6 months of therapy, or
       -  Refractory post-autologous stem cell transplant (ASCT): i. Disease progression
          or relapsed less than or equal to 12 months of ASCT (must have biopsy proven
          recurrence in relapsed individuals); ii. If salvage therapy is given post-ASCT,
          the individual must have had no response to or relapsed after the last line of
          therapy.
     2.4 Individuals who are intolerant to standard treatment can also be included in the
     study in the investigator's judgment.

3. Individuals must have received adequate prior therapy:

3.1 For MCL, prior therapy must have included:

• Anthracycline or bendamustine-containing chemotherapy and
• Anti-CD20 monoclonal antibody (unless investigator determines that tumor is CD20-negative) and
• Bruton's tyrosine kinase inhibitor (BTKi).

3.2 For other types, prior therapy must have included:

• Anti-CD20 monoclonal antibody (unless investigator determines that tumor is CD20-negative) and
• Anthracycline containing chemotherapy regimen.

     3.3 For individual with transformed FL must have relapse or refractory disease after
     transformation to DLBCL.

4. At least 1 measurable lesion: lymph node site with a long axis >1.5cm, extranodal

     site with a long axis >1.0cm (according to the Lugano2014 criteria). Lesions that
     have been previously irradiated will be considered measurable only if progression
     has been documented following completion of radiation therapy.

5. CD19 positive (detected by immunohistochemistry [IHC]).

6. Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1 (except

     for hematological toxicities and clinically non-significant toxicities such as
     alopecia).

7. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

8. Absolute neutrophil count (ANC) ≥ 1 x 10^9/L, Platelet count ≥50 x 10^9/L,

     hemoglobin (Hgb) ≥ 80g/L (hemocytopenia caused by lymphoma invasion of bone marrow
     is not subject to conditions above).

9. Adequate renal, hepatic, pulmonary and cardiac function defined as:

     9.1 Serum creatinine≤1.5 upper limit of normal (ULN) or creatinine clearance (as
     estimated by Cockcroft Gault) ≥ 60 mL/min.
     9.2 Serum alanine aminotransferase / aspartate aminotransferase (ALT/AST) ≤ 3 upper
     limit of normal (ULN); Total bilirubin ≤ 1.5 ULN, except in subjects with 3)
     Gilbert's syndrome.
     9.3 Cardiac ejection fraction ≥ 50%, no evidence of pericardial effusion as
     determined by an echocardiogram (ECHO), and no clinically significant
     electrocardiogram (ECG) findings.
     9.4 Coagulation Function: International Normalized Ratio (INR) ≤ 1.5 times the upper
     limit of normal (ULN), and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 times
     ULN.
     9.5 Baseline oxygen saturation >91% on room air.

10. Subjects of both genders who are willing to practice birth control from the time of

     consent through 6 months after the completion of conditioning chemotherapy. Females
     of childbearing potential must have a negative serum or urine pregnancy test
     (females who have undergone surgical sterilization or who have been postmenopausal
     for at least 2 years are not considered to be of childbearing potential).

11. Voluntarily participate in this clinical trial and sign an informed consent form.

Exclusion Criteria:

1. Expected survival time < 3 months per Principal Investigator's opinion.
2. History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3 years.
3. Autologous stem cell transplant with therapeutic intent within 3 months of planned ATHENA-2 CAR-T infusion.
4. History of allogeneic stem cell transplantation.
5. Patients who received any immunocellular therapy within 3 months before enrollment.
6. Patients who have used any of the following agents or treatments within a specific period of time:

   6.1 Received any chemotherapy drugs or small molecule targeted drugs within 2 weeks prior to lymphodepletion;

   6.2 Received any monoclonal antibodies, antibody drug conjugates (ADCs), or bispecific antibodies within 3 weeks prior to lymphodepletion;

   6.3 Received radiotherapy within 6 weeks prior to lymphodepletion. However, if disease progressed at the site of radiotherapy, or if there are positive lesions detected by PET-CT at non-radiotherapy sites, enrollment is allowed.

7. Subjects with detectable cerebrospinal fluid malignant cells, or brain metastases, or with a history of central nervous system (CNS) lymphoma or primary CNS lymphoma.
8. Presence of donor-specific anti-HLA antibodies directed against ATHENA-2 CAR-T.
9. History of severe, immediate hypersensitivity reaction attributed to lymphodepletion drugs or any component of ATHENA-2 CAR-T.
10. Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous (IV) antimicrobials for management.
11. Uncontrolled or active infectious diseases, such as human immunodeficiency virus (HIV) infection, acute or chronic active hepatitis B or C, epstein-barr virus (EBV), and cytomegalovirus (CMV) infection.
12. History or presence of CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement.
13. Subjects with cardiac atrial or cardiac ventricular lymphoma involvement.
14. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment.
15. Expected or possible requirement for urgent therapy within 6 weeks due to ongoing or impending oncologic emergency (eg, tumor mass effect, tumor lysis syndrome).
16. Primary immunodeficiency.
17. History of autoimmune disease (e.g. Crohn's, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years.
18. History of symptomatic deep vein thrombosis or pulmonary embolism requiring systemic anticoagulation within 6 months of enrollment.
19. Any medical condition likely to interfere with assessment of safety or efficacy of study treatment.
20. History of severe immediate hypersensitivity reaction to any of the agents used in this study.
21. Vaccine ≤ 6 weeks prior to planned start of conditioning regimen.
22. In the investigator's judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.